Torpharm Argument Equating OTC Ranitidine With Rx Doses "Frivolous" - FDA
This article was originally published in The Tan Sheet
Executive Summary
Torpharm's position that 75 mg OTC ranitidine is the same as the 300 mg prescription drug is "frivolous," FDA maintains in a reply document filed April 19 in D.C. federal court in Apotex v. Shalala. The document supports the agency's motion to dismiss the suit. A hearing in the case is scheduled for April 29.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning